Apotex Inc., Canada’s largest drug manufacturer, has won Health Canada approval to sell a generic form of the blockbuster ...

Canada's largest Canadian‑based global health company, today announced that Health Canada has approved Apo‑Semaglutide ...

Health Canada has approved a second generic version of Ozempic, just three days after authorizing the first. The new product, ...

OTTAWA, May 1 (Reuters) - The Canadian health regulator said on Friday that it had approved Canada-based Apotex's generic ...

Apotex Corp. today announced it has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection, marking a ...

The generic medication was developed through a strategic partnership with Orbicular Pharmaceutical Technologies.

Apotex, in collaboration with Orbicular Pharmaceutical Technologies and Gland Pharma, have received permission from the Food ...

TORONTO, April 23, 2026 /PRNewswire/ - Apotex, the largest Canadian based pharmaceutical company, and Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. based specialty pharmaceutical company, ...

Apotex, in collaboration with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited, today announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated ...

U.S. market will not open until patent expires in 2032, but individual generics can be sold in Canada once approved ...

On December 22, 2017, Patillo J. of the Ontario Super Court of Justice held that Apotex was entitled to $11,303,131.80, plus pre-judgment interest, for losses flowing from delays in the US Food and ...

Many biosimilar applicants have resorted to inter partes review (IPR) proceedings to challenge innovator patents as an alternative forum to district court litigation under the BPCIA. For those ...